Cargando…
A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
AIM: To investigate the use of docetaxel for the treatment of metastatic castration‐resistant prostate cancer (mCRPC) in real‐world clinical practice in China. METHODS: This single‐arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 ye...
Autores principales: | He, Dalin, Sun, Zhongquan, Guo, Jianming, Zhang, Zhigen, Shan, Yuxi, Ma, Lulin, Li, Hanzhong, Jin, Jie, Huang, Yiran, Xiao, Jiaquan, Wei, Qiang, Ye, Dingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850484/ https://www.ncbi.nlm.nih.gov/pubmed/30873737 http://dx.doi.org/10.1111/ajco.13142 |
Ejemplares similares
-
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021) -
Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015) -
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
por: Chiang, Ping-Chia, et al.
Publicado: (2023) -
Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022) -
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)